Correlation between the cerebral metabolic rate of glucose on PET/CT with [18F]FDG and clinical, neurocognitive and therapeutic variables after COVID-19

• Grant number: 21/12671-3
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2022
• End date: February 29, 2024
• Field of knowledge: Health Sciences - Medicine - Medical Radiology
• Principal Investigator: Lauro Wichert Ana
• Grantee: Lauro Wichert Ana
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated researchers: Fernando Bellissimo Rodrigues ; Vitor Tumas

Abstract

The SARS-CoV-2 pandemic is a worldwide health problem, characterized by several strains, different levels of severity, and high morbidity. Patients complain of late neurocognitive symptoms between 6 weeks and 12 months after infection. The knowledge gap lies in knowing the topography and pathophysiology of brain involvement, whether due to SARS-CoV-2 neuro infection itself or associated clinical and therapeutic factors. Objectives: (a) To correlate cerebral glycolytic metabolism ([18F]FDG) and cognitive and biomarker alterations after SARS-CoV-2 infection; (b) To correlate the clinical severity, the use of antiplatelet/anticoagulant agents, corticoids, and mechanical ventilation, with late cognitive alterations; (c) Describe the brain areas affected by SARS-CoV-2 infection. Methods: 20 healthy volunteers and 60 patients after SARS-CoV-2 (20 with mild symptoms, 20 moderate, and 20 severe with orotracheal intubation) will be included. Brain PET/CT will be performed with [18F]FDG, current neurological and neuropsychological assessments, and a review of clinical and therapeutic information from the acute and subacute phases. Data will be modeled by PMOD software (PMOD Technologies, Zurich, Switzerland), and 3D images will be displayed by SPM software (UCL, London, UK). Expected results: A protocol for modeling PET/CT findings with clinical, therapeutic, and biomarker variables associated with SARS-CoV-2; supervision of 1 scientific initiation, 1 master's, 1 Ph.D., and 1 postdoctoral researcher and publication of 3 articles in international journals of high impact factor. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ALEXANDRE-SANTOS, LEONARDO; TREVISAN, ANA CAROLINA; PITELLA, FELIPE ARRIVA; TUMAS, VITOR; SILVAH, JOSE HENRIQUE; KATO, MERY; DE MORAES, EDER REZENDE; WICHERT-ANA, LAURO. Assessment of different regions of interest-based methods for [99mTc]Tc DAT-SPECT quantification using an anthropomorphic striatal phantom. EJNMMI PHYSICS, v. 9, n. 1, p. 14-pg., 2022-12-28. (13/25987-2, 21/12671-3)

LIA, ERICA NEGRINI; PAPASSIDERO, PRISCILA COLAVITE; COELHO, EDUARDO BARBOSA; DACH, FABIOLA; ALEXANDRE-SANTOS, LEONARDO; TREVISAN, ANA CAROLINA; LOPES E SANTOS, LUCAS EMMANUEL; SILVAH, JOSE HENRIQUE; LANCHOTE, VERA LUCIA; DELLA PASQUA, OSCAR; et al. Neurobiological substrates of chronic low back pain (CLBP): a brain [Tc-99m]Tc-ECD SPECT study. EUROPEAN JOURNAL OF HYBRID IMAGING, v. 6, n. 1, p. 10-pg., 2022-11-21. (15/50089-3, 21/12671-3)

PITELLA, FELIPE ARRIVA; TREVISAN, ANA CAROLINA; ALEXANDRE-SANTOS, LEONARDO; KATO, MERY; BRITO, MANUELINA MARIANA CAPELLARI MACRUZ; TUMAS, VITOR; WICHERT-ANA, LAURO. Reference Values for Dopamine Transporter Imaging With Tc-99m-TRODAT-1 in Healthy Subjects and Parkinson's Disease Patients. CLINICAL NUCLEAR MEDICINE, v. 47, n. 9, p. 6-pg., 2022-09-01. (15/50089-3, 21/12671-3, 12/14152-4)

PAPASSIDERO, PRISCILA; WICHERT-ANA, LAURO; LIA, ERICA NEGRINI; ALEXANDRE-SANTOS, LEONARDO; TREVISAN, ANA CAROLINA; COELHO, EDUARDO BARBOSA; DELLA PASQUA, OSCAR; LANCHOTE, VERA LUCIA; DACH, FABIOLA. Pharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: a [99mTc]Tc-ECD SPECT study. REGIONAL ANESTHESIA AND PAIN MEDICINE, v. 48, n. 8, p. 6-pg., 2023-03-30. (15/50089-3, 21/12671-3)